低风险重度主动脉瓣狭窄患者TAVI长期证据的审慎解读
本文综述了TAVI对比SAVR在低风险重度主动脉瓣狭窄患者中的长期随访证据。Evolut低风险试验6-7年随访显示主要复合终点无显著差异,但TAVI组晚期死亡率累积、心肌梗死及主动脉瓣再干预率信号升高。PARTNER 3七年结局复合终点大体相似但受方法学限制,PARTNER 2A中危人群10年生存TAVI低于SAVR。作者呼吁在进一步扩大TAVI前建立更严谨透明的长期证据框架。
要点
- Evolut低风险6-7年随访主要复合终点无显著差异,但TAVI组晚期死亡率、心梗及再干预信号升高。
- PARTNER 3七年复合终点大体相似,但受终点构建异质、非预设分析及随访不完整限制。
- PARTNER 2A中危人群10年生存TAVI低于SAVR,再干预率更高。
核心结论
- TAVI在低风险患者中的长期耐久性和再干预负担仍存在不确定性,需审慎扩展适应证。
研究设计与样本
- 本文为综述,整合了Evolut低风险、PARTNER 3、PARTNER 2A等关键试验的长期随访数据及其他新证据。
主要发现
- Evolut低风险6-7年随访主要复合终点(死亡或致残性卒中)无统计学显著差异,但TAVI组显示晚期死亡率累积、心肌梗死事件增多及主动脉瓣再干预率更高的信号。
- PARTNER 3七年复合终点比较大体相似,但解读受终点构建异质、非预设分层分析、随访不完整及事后生命状态确认影响。
- PARTNER 2A中危人群10年生存TAVI低于SAVR,主动脉瓣再干预率更高。
临床怎么用
- 治疗决策应在结构化心脏团队框架内个体化,明确讨论预期生存、解剖适合性、瓣膜耐久性、再干预选择及终身管理影响。
局限性
- PARTNER 3七年结局解读受异质终点构建、非预设分层分析、随访不完整及事后生命状态确认影响。
- 综述整合证据存在异质性,长期随访数据仍不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The expanding use of transcatheter aortic valve implantation (TAVI) in low-risk patients with severe aortic stenosis, including populations underrepresented in pivotal trials and often beyond established guideline recommendations, makes extended follow-up from TAVI versus surgical aortic valve replacement (SAVR) trials central to assessing valve durability and late adverse events and to informing lifetime management strategy. Although Evolut Low Risk 6- to 7-year follow-up showed no statistically significant difference in the primary composite of death or disabling stroke, the signals of later mortality accrual, more myocardial infarction events, and higher aortic valve reintervention rates with TAVI raise concerns about durability and stability of the early treatment effect. In PARTNER 3, 7-year outcomes appeared broadly similar when comparing the reported composite endpoints, but their interpretation is limited by heterogeneous endpoint construction, non-prespecified hierarchical analysis, incomplete follow-up, and the influence of post hoc vital-status ascertainment on late mortality estimates. In an intermediate-risk population, PARTNER 2A showed lower 10-year survival and higher aortic valve reintervention rates with TAVI than with SAVR. Together with the presented UK-TAVI, meta-analyses, and large observational studies, these findings underscore uncertainty about durability and reintervention burden of TAVI and future treatment strategies. By integrating extended follow-up from pivotal trials with other new data, this review calls for a more rigorous and transparent long-term evidence framework before further expanding TAVI, particularly in younger, low-risk patients. Treatment decisions should remain individualized within a structured Heart Team framework, with explicit discussion of expected survival, anatomical suitability, valve durability, reintervention options, and lifetime-management implications.
引用
- Sousa Uva M, Milojevic M, Marin-Cuartas M, et al. Emerging Longer-Term Evidence on Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis in Low-Risk Patients: A Call for Caution. Ann Thorac Surg. 2026. PMID: 42716272. doi:10.1016/j.athoracsur.2026.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。